BB's Stock Haven

[bobafett]

Sterling take a peak at HDVY


all from 10k...

"We have now completed the Abbott clinical trial for Phase 1 and 2 of the urine prostate cancer test validation process. In addition, we have completed all clinical laboratory genomic testing on the clinical trial specimens at MD Anderson Cancer Center. We have fully analyzed the data and are pleased with the results. We have met with and submitted all of our results to Abbott for their independent analysis and are awaiting their comments. If Abbott is satisfied with these results, we expect to receive the $250,000 milestone payment for completion of Phase 1 and 2 and move on to Phase 3 and 4 as described in the FDA Submission Plan. If for some reason Abbott chooses not to move forward, we will immediately begin licensing discussions with other international IVD companies, as well as, clinical laboratories in the US, Europe and China."




"Atlantic Alpha is now exclusively trading SVM’s K-2 model and will begin offering this technology to the public via a new fund which began trading in January 2011. HDC owns a 45% equity position in SVM Capital."

Market cap: 30 million
"The Company has recorded revenue of $2,013,741 from inception through December 31, 2010."

"At December 31, 2010, the Company had $3,295,630 in cash and cash equivalents and total current liabilities of $1,079,073. Additionally, during the first quarter of 2011, we received approximately $135,156 in cash from the receipt of a final payment under the Qualified Therapeutic Development Program (“QTDP”) grant program from the United States Government. On March 30, 2011, our total cash and cash equivalents was approximately $2,500,000. "

"The Company plans to initiate its new academic/research institution licensing program in the second quarter of 2011. Universities and research institutions that have reported the use of SVMs in published reports such as academic journals and conference proceedings will be contacted and offered a paid-up license against past and future infringement of the Company’s patented technology for a nominal one-time license administrative fee plus a percentage of any revenue generated when the results of the SVM usage are licensed for commercialization. The program will begin first with admitted usages of the Company’s SVM-RFE method. To date, over 30 U.S. institutions have been identified as using RFE through review of academic publications, with many of the reported uses relating to biomarker discovery and medical diagnostics. The Company plans to expand its licensing efforts to European institutions once all formalities have been completed for validation of the recently-granted European SVM-RFE patent. The program will later be broadened to other reported uses of SVM and other technology covered by the Company’s patents."






http://www.sec.gov/Archives/edgar/data/1141788/000118811211000819/t70200_10k.htm

HDVY - Daily Candlesticks

Another wolv

HDVY - Daily Candlesticks